Rosa Bellota, MD
Child & Adolescent Psychiatry · Las Vegas, NVNPI 1811280183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 30.3% of the total. Reporting peaked in 2019 at $751 and has fallen 89.8% since, to $76 in 2024.
Across 72 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393
- Shire North American Group Inc$155
- Otsuka America Pharmaceutical, Inc.$142
- Takeda Pharmaceuticals U.S.A., Inc.$123
- Eisai Inc.$61
- Lundbeck LLC$58
- plus $362 from 11 others
What the payments were for
- Food & beverage$1,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$248
How this compares
$1,294 in reported general payments places this provider in the 75th percentile of 26 child & adolescent psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 16 | $198 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $81 |
| Alprazolam | 24 | $74 |
| Zolpidem Tartrate | 13 | $20 |
| Lamotrigine | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Las Vegas
- Ann ChildressLas Vegas$1.4M
- Joan CarapucciLas Vegas$7K
- Emmanuel NwapaLas Vegas$7K
- Michelle Fontenelle-GilmerLas Vegas$904
- Corydon ClarkLas Vegas$777
- Nina ParikhLas Vegas$516
- Fernando MendezLas Vegas$249
- Colin FreedmanLas Vegas$198
- Olayinka HardingLas Vegas$16
- Jerome NwokikeNorth Las Vegas$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.